Phibro Animal Health (PAHC) Non-Current Debt (2013 - 2026)
Phibro Animal Health's (PAHC) quarterly Non-Current Debt came in at $597.7 million in Q1 2026, down 3.47% year-on-year from $619.2 million in Q1 2025, and down 0.98% quarter-over-quarter from $603.6 million in Q4 2025.
Phibro Animal Health (PAHC) Non-Current Debt (2013 - 2026) Analysis & Trends
Phibro Animal Health's Non-Current Debt history runs 14 years deep, the most recent figure standing at $597.7 million for Q1 2026.
- On a quarterly basis, Non-Current Debt fell 3.47% year-over-year to $597.7 million in Q1 2026; TTM through Mar 2026 was $597.7 million, a 3.47% decrease from a year earlier, with the FY2025 full-year figure at $87.0 million, down 50.57% from the prior year.
- Non-Current Debt retreated to $597.7 million in Q1 2026 per PAHC's latest filing, from $603.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $619.2 million in Q1 2025 and bottomed at $87.0 million in Q2 2025.
- The 5-year median for Non-Current Debt is $179.0 million (2024), against an average of $280.2 million.
- Across the five-year window, Non-Current Debt sank 61.73% in 2024 and jumped 429.48% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $276.8 million in 2022, then grew by 7.6% to $297.9 million in 2023, then sank by 61.73% to $114.0 million in 2024, then soared by 429.48% to $603.6 million in 2025, then fell by 0.98% to $597.7 million in 2026.
- Per Business Quant, the three latest PAHC Non-Current Debt figures stand at $597.7 million (Q1 2026), $603.6 million (Q4 2025), and $609.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Phibro Animal Health | 1.38 Bn | 1.30 Bn | 125.68 Mn | 597.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 597.69 Mn |
| Dec 31, 2025 | 603.60 Mn |
| Sep 30, 2025 | 609.52 Mn |
| Jun 30, 2025 | 87.00 Mn |
| Mar 31, 2025 | 619.16 Mn |
| Dec 31, 2024 | 114.00 Mn |
| Sep 30, 2024 | 179.00 Mn |
| Jun 30, 2024 | 176.00 Mn |
| Mar 31, 2024 | 165.00 Mn |
| Dec 31, 2023 | 297.85 Mn |
| Sep 30, 2023 | 154.00 Mn |
| Jun 30, 2023 | 141.00 Mn |
| Mar 31, 2023 | 193.00 Mn |
| Dec 31, 2022 | 276.81 Mn |
| Sep 30, 2022 | 280.74 Mn |
| Jun 30, 2022 | 145.00 Mn |
| Mar 31, 2022 | 124.00 Mn |
| Dec 31, 2021 | 280.32 Mn |
| Sep 30, 2021 | 110.00 Mn |
| Jun 30, 2021 | 95.00 Mn |